Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,154,395
  • Shares Outstanding, K 73,787
  • Annual Sales, $ 5,450 K
  • Annual Income, $ -325,100 K
  • 60-Month Beta 0.83
  • Price/Sales 579.11
  • Price/Cash Flow N/A
  • Price/Book 4.27
Trade SWTX with:

Options Overview Details

View History
  • Implied Volatility 87.43% ( +0.70%)
  • Historical Volatility 38.04%
  • IV Percentile 88%
  • IV Rank 42.32%
  • IV High 128.76% on 11/27/23
  • IV Low 57.11% on 09/20/23
  • Put/Call Vol Ratio 0.24
  • Today's Volume 205
  • Volume Avg (30-Day) 287
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 8,790
  • Open Int (30-Day) 7,411

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.19
  • Number of Estimates 5
  • High Estimate -0.93
  • Low Estimate -1.35
  • Prior Year -1.18
  • Growth Rate Est. (year over year) -0.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.89 +1.48%
on 04/10/24
52.52 -19.06%
on 03/21/24
-7.77 (-15.45%)
since 03/15/24
3-Month
37.95 +12.02%
on 01/18/24
53.92 -21.16%
on 03/08/24
+1.58 (+3.86%)
since 01/12/24
52-Week
18.00 +136.17%
on 11/13/23
53.92 -21.16%
on 03/08/24
+18.58 (+77.64%)
since 04/14/23

Most Recent Stories

More News
5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

$SPX : 5,061.82 (-1.20%)
NVO : 123.90 (-0.49%)
BIIB : 196.80 (-0.70%)
KNSA : 17.44 (+0.87%)
SWTX : 42.51 (-0.56%)
RLAY : 6.83 (-2.84%)
ADPT : 2.91 (-3.32%)
GS : 400.88 (+2.92%)
SpringWorks Therapeutics: Q4 Earnings Snapshot

SpringWorks Therapeutics: Q4 Earnings Snapshot

SWTX : 42.51 (-0.56%)
SpringWorks Therapeutics: Q3 Earnings Snapshot

SpringWorks Therapeutics: Q3 Earnings Snapshot

SWTX : 42.51 (-0.56%)
SpringWorks Therapeutics: Q2 Earnings Snapshot

SpringWorks Therapeutics: Q2 Earnings Snapshot

SWTX : 42.51 (-0.56%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 7.15 (-4.16%)
DAWN : 13.85 (+0.58%)
SWTX : 42.51 (-0.56%)
VSTM : 11.07 (-2.04%)
KNTE : 2.65 (-0.38%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 7.15 (-4.16%)
SWTX : 42.51 (-0.56%)
DAWN : 13.85 (+0.58%)
VSTM : 11.07 (-2.04%)
KNTE : 2.65 (-0.38%)
SpringWorks Therapeutics: Q1 Earnings Snapshot

SpringWorks Therapeutics: Q1 Earnings Snapshot

SWTX : 42.51 (-0.56%)
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s...

BGNE : 138.40 (-2.05%)
SWTX : 42.51 (-0.56%)
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b...

BGNE : 138.40 (-2.05%)
SWTX : 42.51 (-0.56%)
SpringWorks Therapeutics: Q4 Earnings Snapshot

SpringWorks Therapeutics: Q4 Earnings Snapshot

SWTX : 42.51 (-0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics...

See More

Key Turning Points

3rd Resistance Point 44.83
2nd Resistance Point 44.23
1st Resistance Point 43.37
Last Price 42.51
1st Support Level 41.91
2nd Support Level 41.30
3rd Support Level 40.44

See More

52-Week High 53.92
Last Price 42.51
Fibonacci 61.8% 40.20
Fibonacci 50% 35.96
Fibonacci 38.2% 31.72
52-Week Low 18.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar